Q1 Earnings Forecast for FibroGen Issued By William Blair

FibroGen, Inc. (NASDAQ:FGEN) – Analysts at William Blair issued their Q1 2026 EPS estimates for shares of FibroGen in a report released on Tuesday, April 1st. William Blair analyst A. Hsieh expects that the biopharmaceutical company will earn ($0.21) per share for the quarter. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($0.80) per share. William Blair also issued estimates for FibroGen’s Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.22) EPS and Q4 2026 earnings at ($0.22) EPS.

Other analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of FibroGen in a research note on Tuesday, March 18th. StockNews.com assumed coverage on FibroGen in a research report on Sunday, March 30th. They set a “hold” rating for the company.

FibroGen Stock Performance

FGEN opened at $0.28 on Thursday. The stock’s 50 day moving average price is $0.44 and its 200-day moving average price is $0.42. FibroGen has a one year low of $0.18 and a one year high of $1.74. The stock has a market cap of $28.26 million, a price-to-earnings ratio of -0.23 and a beta of 0.82.

FibroGen (NASDAQ:FGEN) last announced its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). The company had revenue of $3.14 million during the quarter, compared to analysts’ expectations of $24.91 million.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Two Sigma Securities LLC acquired a new stake in shares of FibroGen in the fourth quarter worth $27,000. Velan Capital Investment Management LP acquired a new stake in FibroGen during the 4th quarter worth about $42,000. XTX Topco Ltd raised its stake in shares of FibroGen by 423.8% during the 4th quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 77,693 shares during the last quarter. Franklin Street Advisors Inc. NC lifted its holdings in shares of FibroGen by 100.0% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 100,000 shares during the period. Finally, FMR LLC boosted its stake in shares of FibroGen by 21.8% in the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 68,569 shares during the last quarter. 72.71% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at FibroGen

In other FibroGen news, CEO Thane Wettig purchased 145,000 shares of the firm’s stock in a transaction on Monday, March 24th. The stock was bought at an average cost of $0.35 per share, for a total transaction of $50,750.00. Following the completion of the purchase, the chief executive officer now owns 543,329 shares in the company, valued at $190,165.15. This represents a 36.40 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James A. Schoeneck acquired 250,000 shares of the business’s stock in a transaction dated Thursday, March 20th. The shares were bought at an average price of $0.35 per share, for a total transaction of $87,500.00. Following the acquisition, the director now owns 323,722 shares of the company’s stock, valued at approximately $113,302.70. This represents a 339.11 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.98% of the stock is owned by insiders.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.